{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:18:57Z","timestamp":1779304737148,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Shaanxi Province, Key Industrial Innovation Project Fund","award":["2023-ZDLSF-44"],"award-info":[{"award-number":["2023-ZDLSF-44"]}]},{"name":"National Natural Science Foundation of China General Program","award":["No. 82370588"],"award-info":[{"award-number":["No. 82370588"]}]},{"name":"National Natural Science Foundation of China Major Research Program Integration Project","award":["No. 92259302"],"award-info":[{"award-number":["No. 92259302"]}]},{"name":"Independent Funds of the Key Laboratory","award":["CBSKL2022ZZ34"],"award-info":[{"award-number":["CBSKL2022ZZ34"]}]},{"name":"Airforce Foundation"},{"name":"Young Changjiang Scholars of the Ministry of Education"},{"name":"Medical Personnel Training and Promotion Program of Xijing Hospital","award":["XJZT24QN41"],"award-info":[{"award-number":["XJZT24QN41"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01468-z","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T11:02:23Z","timestamp":1727694143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness and safety of upadacitinib in acute severe ulcerative colitis patients from single Chinese IBD Center: a monocentric study"],"prefix":"10.1007","volume":"24","author":[{"given":"Jiaqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaichun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"9853","key":"1468_CR1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"I Ordas","year":"2012","unstructured":"Ordas I, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606\u201319.","journal-title":"Lancet"},{"issue":"11","key":"1468_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrgastro.2016.116","volume":"13","author":"P Hindryckx","year":"2016","unstructured":"Hindryckx P, Jairath V, D\u2019Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13(11):654\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"1468_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450\u201361.","journal-title":"Gastroenterology"},{"issue":"8","key":"1468_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/ueg2.12442","volume":"11","author":"L Calmejane","year":"2023","unstructured":"Calmejane L, et al. Review article: updated management of acute severe ulcerative colitis: from steroids to novel medical strategies. United Eur Gastroenterol J. 2023;11(8):722\u201332.","journal-title":"United Eur Gastroenterol J"},{"key":"1468_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/CEG.S197719","volume":"14","author":"T Holvoet","year":"2021","unstructured":"Holvoet T, Lobaton T, Hindryckx P. Optimal management of acute severe ulcerative colitis (ASUC): challenges and solutions. Clin Exp Gastroenterol. 2021;14:71\u201381.","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"1468_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1017\/S1352465819000444","volume":"48","author":"F Bennebroek Evertsz","year":"2020","unstructured":"Bennebroek Evertsz F, et al. I am a total failure: associations between beliefs and anxiety and depression in patients with inflammatory bowel disease with poor mental quality of life. Behav Cogn Psychother. 2020;48(1):91\u2013102.","journal-title":"Behav Cogn Psychother"},{"issue":"1","key":"1468_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00054725-200501000-00004","volume":"11","author":"SW Han","year":"2005","unstructured":"Han SW, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005;11(1):24\u201334.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1468_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","volume":"17","author":"JP Gisbert","year":"2023","unstructured":"Gisbert JP, Garcia MJ, Chaparro M. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review. J Crohns Colitis. 2023;17(6):972\u201394.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"1468_CR9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","volume":"119","author":"A Singh","year":"2024","unstructured":"Singh A, et al. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol. 2024;119(7):1365\u201372.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"1468_CR10","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","volume":"17","author":"C Steenholdt","year":"2023","unstructured":"Steenholdt C, et al. Tofacitinib for acute severe ulcerative colitis: a systematic review. J Crohns Colitis. 2023;17(8):1354\u201363.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"1468_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/apt.16463","volume":"54","author":"M Uzzan","year":"2021","unstructured":"Uzzan M, et al. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort. Aliment Pharmacol Ther. 2021;54(3):312\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1468_CR12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","volume":"21","author":"S Friedberg","year":"2023","unstructured":"Friedberg S, et al. upadacitinib is effective and safe in both ulcerative colitis and crohn\u2019s disease: prospective real-world experience. Clin Gastroenterol Hepatol. 2023;21(7):1913\u201323.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1468_CR13","unstructured":"AbbVie. RINVOQ\u00ae(upadacitinib) extended-release tablets, US Prescribing Information. 2022; Available from: https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf"},{"key":"1468_CR14","unstructured":"Em A. RINVOQ summary of product characteristics. European Medicines Agency. 2022; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq#assessment-history-section"},{"issue":"12","key":"1468_CR15","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","volume":"17","author":"R Gilmore","year":"2023","unstructured":"Gilmore R, et al. Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. J Crohns Colitis. 2023;17(12):2033\u20136.","journal-title":"J Crohns Colitis"},{"key":"1468_CR16","first-page":"9","volume":"38","author":"Infammatory Bowel Disease Group, CSoG, Chinese Medical Association","year":"2018","unstructured":"Infammatory Bowel Disease Group, CSoG, Chinese Medical Association. Chinese consensus on diagnosis and treatment of infammatory bowel disease(Beijing, 2018). Chin J Pract Intern Med. 2018;38:9.","journal-title":"Chin J Pract Intern Med"},{"key":"1468_CR17","unstructured":"Services, USDoHaH. Food and drug administration and center for drug evaluation and research (CDER). Ulcerative colitis: clinical trial endpoints. Guidance for industry. 2016; Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM515143.pdf"},{"issue":"9","key":"1468_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jama.2023.1084","volume":"329","author":"S Zhang","year":"2023","unstructured":"Zhang S, et al. Effect of induction therapy with olamkicept vs placebo on clinical response in patients with active ulcerative colitis: a randomized clinical trial. JAMA. 2023;329(9):725\u201334.","journal-title":"JAMA"},{"issue":"8","key":"1468_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/ecco-jcc\/jjv077","volume":"9","author":"SP Travis","year":"2015","unstructured":"Travis SP, et al. The impact of clinical information on the assessment of endoscopic activity: characteristics of the ulcerative colitis endoscopic index of severity [UCEIS]. J Crohns Colitis. 2015;9(8):607\u201316.","journal-title":"J Crohns Colitis"},{"issue":"11","key":"1468_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1136\/gutjnl-2016-312722","volume":"65","author":"A Marchal-Bressenot","year":"2016","unstructured":"Marchal-Bressenot A, et al. A practical guide to assess the Nancy histological index for UC. Gut. 2016;65(11):1919\u201320.","journal-title":"Gut"},{"issue":"6","key":"1468_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","volume":"38","author":"SP Travis","year":"1996","unstructured":"Travis SP, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905\u201310.","journal-title":"Gut"},{"issue":"8","key":"1468_CR22","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139\u201349.","journal-title":"Gastroenterology"},{"issue":"10341","key":"1468_CR23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113\u201328.","journal-title":"Lancet"},{"issue":"10214","key":"1468_CR24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019;394(10214):2108\u201317.","journal-title":"Lancet"},{"issue":"1","key":"1468_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gastrohep.2020.04.012","volume":"44","author":"A Lopez-Sanroman","year":"2021","unstructured":"Lopez-Sanroman A, Esplugues JV, Domenech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol. 2021;44(1):39\u201348.","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"1468_CR26","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87(4):784\u201391.","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01468-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01468-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01468-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:08:29Z","timestamp":1732986509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01468-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01468-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki, and proved by the Medical Ethics Committee of the First Affiliated Hospital of the Air Force Medical University (Reference Number: KY20232125-C-I). Informed consent was obtained from all patients. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u00a0This is an open access article under.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"233"}}